How much does one dose of Adalimumab cost? Latest market quotation reference

Adalimumab (Humira®) is a humanized monoclonal antibody against TNF-α, used to treat autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriasis and Crohn's disease. At present, it has been successfully included in Class B medical insurance in China, and the cost has been significantly reduced, which has better alleviated the financial burden of patients.

According to the results of the medical insurance negotiation, the price of the original research Humira® has increased from about 7,600yuan< span>/The payment is directly reduced to approximately 1,290 yuan/ payment, becoming the standard price for medical insurance payment. This price reduction of more than 80% makes this biologic affordable for many patients. There are also a number of domestic biosimilar drugs on the market, such as "Glory®", "An Jianning" and "Su Lixin" an>", its price is between 1,150–1,160yuan/, slightly lower than the standard price of medical insurance.

In the latest market quotations for 2025, the prices of domestic original research and biosimilar drugs are similar, generally between 1,150–1,400 yuan/ yuan. According to Dingxiangtong data, the current retail price of Humira® injection, mainly produced in Germany, ranges from 1,290–1,400 yuan/ yuan. Patients can also refer to this price range when purchasing from hospitals or designated pharmacies in various places.

In general, adalimumab is already a routine treatment drug covered by medical insurance in China, and the price per tube has stabilized at a reasonable range of 1,200–1,400 yuan. At the same time, a number of domestic biosimilar drugs have entered the market with slightly lower prices, giving patients more choices. The actual cost will also be affected by hospital procurement, medical insurance policies and regional differences. It is recommended that patients go to their hospital or medical insurance department for specific consultation.

Reference materials:https://www.drugs.com/donanemab.html